On 14th July 2025, the commencement ceremony for the Singapore Drug Product (DP) modular plant project, a collaboration between WuXi Biologics and Pharmadule Morimatsu, was held at the Morimatsu Changshu Plant.It marks a further deepening of the collaboration between WuXi Biologics and Pharmadule Morimatsu. Upon completion, the facility will become one of the world’s largest modular biologics DP manufacturing plant, significantly strengthening Singapore’s position as a state-of-the-art core biopharmaceutical production base. 

Pharmadule Morimatsu will fabricate and assemble 470 modules to establish the DP Modular Plant Facility which will have a total floor area of approximately 30,000 m². The facility will house an integrated DP production plant with multiple finished-dosage-form consisting of vials and pre-filled syringes as well as Quality Control (QC) laboratories with full release and stability capability, and Manufacturing Science and Technology (MSAT) laboratories. It will commence operations in 2027.

Since the detailed design phase officially commenced, the teams from both companies haveworked efficiently and collaboratively. Within just six months, the companies have not only completed the vast majority of core design work but have alsosimultaneously and efficiently advancedprocurement and the manufacturing of steel structure modules. The successful achievement of these critical milestones fully demonstrates Pharmadule Morimatsu’s exceptional project management and execution capabilities in large-scale complex modular projects, establishing a solid foundation for the project's commencement and subsequent construction phases. 

Mr.Weihua Tang, CEO of Morimatsu LifeSciences stated,“We are honored to continue supporting WuXi Biologics in building its advanced biologics DP manufacturing facility in Singapore. The DP building will adopt a flexible, efficient, and sustainable modular construction approach, achieving deep integration of factory modules and process modules. As a trusted partner, Pharmadule Morimatsu will fully support WuXi Biologics in advancing the manufacturing facility in Singapore, contributing to the progress and prosperity of the biopharmaceutical industry.” 

About Morimatsu LifeSciences

Morimatsu LifeSciences is a key business segment of Morimatsu International Holdings Limited (Stock Code: 2155.HK). It comprises Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) LifeSciences Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Shanghai Mori-Biounion Technology Co., Ltd., Shanghai Morisora Technology Co., Ltd., Pharmadule Morimatsu AB, and its affiliated companies.

Morimatsu LifeSciences is dedicated in providing core equipment, process systems, and smart modular facility solutions, and services for the pharmaceutical, biopharmaceutical, medical aesthetics, and fast-moving consumer goods (FMCG) sectors including (cosmetics, food, and health supplements), as well as data centers.

Our team comprises highly experienced professionals with deep expertise in process R&D, engineering design, advanced manufacturing, compliance and validation consulting, production execution, and intelligent operations. With broad experience across diverse industries, we fully understand the unique characteristics and process requirements of various products. This enables us to deliver tailored, end-to-end process solutions from the conceptual design stage, precisely aligned with client’s specific needs.

Morimatsu LifeSciences has established a strong global presence, supported by advanced R&D centers, design hubs, and state-of-the-art manufacturing facilities worldwide. Our well-established service network spans Europe,USA,Asia-Pacific, and emerging markets. We have successfully delivered outstanding, customized solutions to clients in over 40 countries and regions, gaining extensive experience in international project execution.

As a multinational enterprise with core strengths in process technology, modular facility construction, and intelligent manufacturing, Morimatsu LifeSciences is dedicated to meeting the evolving equipment and system needs of our key industries. Through continuous innovation and technological advancement, we are steadily expanding our global footprint, driving our international strategy forward, and delivering Morimatsu’s expertise, reliability, and innovation to the global life sciences and related sectors.

About Pharmadule

Since its establishment in 1986, Pharmadule(a member of Morimatsu Group since 2011) has delivered more than 90 production facilities in pharma and biopharma industries globally as well as completed more than 300 engineering designs and solution validations which demonstrates us as the integrated, holistic facility as well as core process equipment leading provider in the world.